Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Correlation and coexpression of HIFs and NOTCH markers in NSCLC.

Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Stenvold H, Busund LT, Bremnes RM.

Anticancer Res. 2011 May;31(5):1603-6.

PMID:
21617216
2.

Association of FOXP3 expression with non-small cell lung cancer.

Dimitrakopoulos FI, Papadaki H, Antonacopoulou AG, Kottorou A, Gotsis AD, Scopa C, Kalofonos HP, Mouzaki A.

Anticancer Res. 2011 May;31(5):1677-83.

PMID:
21617226
3.

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL.

Br J Cancer. 2001 Sep 14;85(6):881-90.

4.

Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer.

Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P.

BMC Cancer. 2010 Jun 23;10:323. doi: 10.1186/1471-2407-10-323.

5.

Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.

Pelosi G, Fraggetta F, Pasini F, Maisonneuve P, Sonzogni A, Iannucci A, Terzi A, Bresaola E, Valduga F, Lupo C, Viale G.

Am J Surg Pathol. 2001 Mar;25(3):363-72.

PMID:
11224607
6.

Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.

Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, Fujisawa T.

Cancer. 2007 Jun 15;109(12):2506-14.

7.

L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.

Imai H, Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M.

Histopathology. 2009 Jun;54(7):804-13. doi: 10.1111/j.1365-2559.2009.03300.x.

PMID:
19635099
8.

Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients.

Hastings RH, Laux AM, Casillas A, Xu R, Lukas Z, Ernstrom K, Deftos LJ.

Clin Cancer Res. 2006 Jan 15;12(2):499-506. Erratum in: Clin Cancer Res. 2006 Jul 1;12(13):4130.

9.

Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.

Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY.

Clin Cancer Res. 2002 Dec;8(12):3796-802. Erratum in: Clin Cancer Res. 2003 Feb;9(2):915.. Gong Koo [corrected to Kong Gu].

10.

Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M.

Cancer Sci. 2003 Apr;94(4):394-9.

11.

Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study.

Małusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z.

Anticancer Res. 2001 Mar-Apr;21(2A):1015-21.

PMID:
11396134
12.

Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma.

Sánchez-Ceja SG, Reyes-Maldonado E, Vázquez-Manríquez ME, López-Luna JJ, Belmont A, Gutiérrez-Castellanos S.

Lung Cancer. 2006 Nov;54(2):163-8. Epub 2006 Sep 7.

PMID:
16959370
13.

CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M.

Ann Surg Oncol. 2009 Dec;16(12):3473-81. doi: 10.1245/s10434-009-0685-0. Epub 2009 Sep 24.

PMID:
19777189
14.

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.

Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, Muzik H, Stolte E, Boland W, Morris D, Magliocco AM, Bebb DG.

J Thorac Oncol. 2011 Jul;6(7):1169-78. doi: 10.1097/JTO.0b013e3182199a99.

15.

Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer.

Yu S, Sun J, Zhang J, Xu X, Li H, Shan B, Tian T, Wang H, Ma D, Ji C.

Histol Histopathol. 2013 Feb;28(2):277-84. doi: 10.14670/HH-28.277.

PMID:
23275310
16.

Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.

Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.

Cancer. 2005 Apr 15;103(8):1676-84.

17.

Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.

Ishikawa S, Nakagawa T, Miyahara R, Kawano Y, Takenaka K, Yanagihara K, Otake Y, Katakura H, Wada H, Tanaka F.

Clin Cancer Res. 2005 Feb 1;11(3):1198-202.

18.

[Expression and significance of Elf-1 and vascular endothelial growth factor in non-small cell lung cancer].

Yang DX, Han YC, Liu LY, Yu N, Wang X, Shi Y.

Ai Zheng. 2009 Jul;28(7):762-7. Chinese.

PMID:
19624906
19.

[Correlation of DNA-dependent protein kinase catalytic subunit expression to radiosensitivity of non-small cell lung cancer cell lines].

Pan Y, Li WX, Li JM, Zhu JQ, Liang YQ, Guo AL.

Ai Zheng. 2009 Jul;28(7):714-7. Chinese.

PMID:
19624897
20.

Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer.

Tanaka F, Takata T, Yamada T, Yanagihara K, Otake Y, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Inui K, Wada H.

Lung Cancer. 2002 Apr;36(1):27-32.

PMID:
11891030

Supplemental Content

Support Center